Veracyte (VCYT) Stock Price, News & Analysis

Company Overview

Veracyte, Inc. is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules. In addition, Veracyte offers the Percepta Genomic Sequencing Classifier for patients with lung nodules, as well as the Envisia Genomic Classifier for patients with suspected interstitial lung disease. These tests leverage RNA sequencing and advanced bioinformatics to deliver clinically actionable results, enabling more precise risk stratification and management of patients.

Veracyte operates certified laboratories in South San Francisco and Europe, serving a broad network of endocrinologists, pulmonologists and pathologists across the United States, Canada and selected European markets. The company collaborates with healthcare organizations and specialty groups to integrate its tests into diagnostic workflows, supporting evidence-based medicine and cost-effective care. Veracyte’s commercial operations are supported by a field sales force, partnerships with reference laboratories and direct engagement with key opinion leaders in oncology and pulmonary medicine.

Under the leadership of CEO Bonnie H. Anderson, Veracyte has pursued strategic growth initiatives, including the expansion of its test menu and development of new molecular classifiers. The company’s management team combines expertise in genomics, diagnostic development and commercial operations, positioning Veracyte to advance its pipeline and capitalize on emerging opportunities in precision diagnostics. By continuing to innovate in genomic science and build strategic partnerships, Veracyte aims to expand access to its tests and further enhance diagnostic accuracy worldwide.

Key Stats

• Today's Range: $29.38 to $30.51
• 50-Day Range: $23.03 to $31.00
• 52-Week Range: $22.61 to $47.32
• Volume: 829,196 shs
• Average Volume: 1.25 million shs
• Market Capitalization: $2.37 billion
• P/E Ratio: 91.25
• Dividend Yield: N/A
• Price Target: $40.90
• Consensus Rating: Moderate Buy

Veracyte Stock Analysis - MarketRank™

Veracyte scored higher than 60% of companies evaluated by MarketBeat, and ranked 504th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Veracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Veracyte has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 5.88%

Earnings Growth

Earnings for Veracyte are expected to grow by 5.88% in the coming year, from $0.68 to $0.72 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Veracyte is 91.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 269.20.

Price to Earnings Ratio vs. Sector

The P/E ratio of Veracyte is 91.25, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 82.98.

Price to Book Value per Share Ratio

Veracyte has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for VCYT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veracyte does not currently pay a dividend.

Dividend Growth

Veracyte does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.10

Short Interest

There is no current short interest data available for VCYT.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.10

News Sentiment

Veracyte has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Veracyte this week, compared to 8 articles on an average week.

Search Interest

Only 4 people have searched for VCYT on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Veracyte to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Veracyte insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.40% of the stock of Veracyte is held by insiders.

VCYT Stock Analysis - Frequently Asked Questions

How have VCYT shares performed this year?

Veracyte's stock was trading at $39.60 at the start of the year. Since then, VCYT shares have decreased by 24.0% and is now trading at $30.11.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) issued its earnings results on Monday, February, 24th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.07. The biotechnology company earned $118.63 million during the quarter, compared to the consensus estimate of $110.73 million. Veracyte had a trailing twelve-month return on equity of 6.07% and a net margin of 5.50%.
Read the conference call transcript.

Does Veracyte have any subsidiaries?

Veracyte subsidiaries include these companies: HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.

Who are Veracyte's major shareholders?

Top institutional shareholders of Veracyte include Artisan Partners Limited Partnership (8.04%), ARK Investment Management LLC (4.85%), State Street Corp (4.03%) and Geode Capital Management LLC (2.47%). Insiders that own company stock include Rebecca Chambers, John Leite, Giulia C Kennedy, Bonnie H Anderson, Jonathan Wygant, Jonathan Wygant, Evan/ Fa Jones, John L Bishop, Jens Holstein, Muna Bhanji and Karin Eastham.
View institutional ownership trends.

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 2/24/2025
• Today: 9/02/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:VCYT
• CIK: 1384101
• Web: www.veracyte.com
• Phone: (650) 243-6300
• Fax: 650-243-6301
• Employees: 790
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Veracyte: $40.90
• High Price Target: $50.00
• Low Price Target: $28.00
• Potential Upside/Downside: +35.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.33
• Trailing P/E Ratio: 91.25
• Forward P/E Ratio: 44.28
• P/E Growth: N/A
• Net Income: $24.14 million
• Net Margins: 5.50%
• Pretax Margin: 6.05%
• Return on Equity: 6.07%
• Return on Assets: 5.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.43
• Quick Ratio: 5.10

Sales & Book Value

• Annual Sales: $445.76 million
• Price / Sales: 5.31
• Cash Flow: $1.03 per share
• Price / Cash Flow: 29.26
• Book Value: $15.52 per share
• Price / Book: 1.94

Miscellaneous

• Outstanding Shares: 78,670,000
• Free Float: 77,571,000
• Market Cap: $2.37 billion
• Optionable: Optionable
• Beta: 2.07